Drugs.com - New Drug Approvals

FDA Approves Imaavy (nipocalimab-aahu) for the Treatment of Generalized Myasthenia Gravis (gMG)

SPRING HOUSE, Pa., (April 30, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved Imaavy (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the treatment of...

Apr 30, 2025 - 22:55
 0
FDA Approves Imaavy (nipocalimab-aahu) for the Treatment of Generalized Myasthenia Gravis (gMG)
SPRING HOUSE, Pa., (April 30, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved Imaavy (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the treatment of...
Read More

Tags:

Previous Article

Rinvoq (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

Next Article

New Saw Offers Precision, Power and Flexibility in One Package

Related Posts

Mirum’s Livmarli Now FDA Approved in Tablet Formulation

Mirum’s Livmarli Now FDA Approved in Tablet Formulation

Apr 26, 2025  0

Bavarian Nordic Receives U.S. FDA Approval of Jynneos Freeze-Dried Smallpox and Mpox Vaccine

Bavarian Nordic Receives U.S. FDA Approval of Jynneos F...

Apr 26, 2025  0

FDA Approves Osenvelt (denosumab-bmwo), a Biosimilar to Xgeva

FDA Approves Osenvelt (denosumab-bmwo), a Biosimilar to...

Apr 26, 2025  0